Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 40 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Panidis, Dimitrios [Clear All Filters]
Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss..
Obes Facts. 5(4), 495-504.
(2012). Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients..
Fertil Steril. 92(6), 2078-81.
(2009). Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome..
Gynecol Endocrinol. 29(10), 926-30.
(2013). Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels..
Am J Physiol Endocrinol Metab. 296(2), E238-43.
(2009). Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome..
Eur J Endocrinol. 168(2), 145-52.
(2013). Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels..
Eur J Endocrinol. 165(1), 63-8.
(2011). The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome..
Eur J Endocrinol. 168(6), 871-7.
(2013).
(2013).
(2012). Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome..
Eur J Obstet Gynecol Reprod Biol. 149(2), 170-4.
(2010). Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS)..
Gynecol Endocrinol. 29(3), 242-5.
(2013). Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome..
Hormones (Athens). 12(4), 559-66.
(2013). The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia..
Fertil Steril. 91(4 Suppl), 1427-30.
(2009). Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome..
Fertil Steril. 91(6), e1.
(2009). The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome..
Endocr J. 58(4), 237-46.
(2011). The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study..
Reprod Biol Endocrinol. 8, 151.
(2010). Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment..
Curr Vasc Pharmacol. 13(6), 788-800.
(2015).
(2013).
Hormone therapy and asymmetrical dimethylarginine in postmenopausal women..
Hormones (Athens). 9(2), 127-35.
(2010).
(2011).
(2012).
(2013).
(2014).
Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance..
Fertil Steril. 91(4), e3; author reply e4.
(2009).
(2011).